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ABSTRACT The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is
controversial. We examined the relationship between lymphoid infiltration patterns in NSCLC and prognosis.
Tumour- and stroma-infiltrating CD3+, CD8+ and forkhead box P3 (Foxp3)+ T-lymphocytes were
identified using immunohistochemistry and a novel image analysis algorithm to assess total, cytotoxic and
regulatory T-lymphocyte counts, respectively, in 196 NSCLC cases. The median cell count was selected as
a cut-point to define patient subgroups and the ratio of the corresponding tumour islet:stroma (TI/S)
counts was determined.
There was a positive association between overall survival and increased CD8+ TI/S ratio (hazard ratio
(HR) for death 0.44, p<0.001) but an inverse relationship between Foxp3+ TI/S ratio and overall survival
(HR 4.86, p<0.001). Patients with high CD8+ islet (HR 0.48, p<0.001) and Foxp3+ stromal (HR 0.23,
p<0.001) counts had better survival, whereas high CD3+ and CD8+ stromal counts and high Foxp3+ islet
infiltration conferred a worse survival (HR 1.55, 2.19 and 3.14, respectively). By multivariate analysis, a
high CD8+ TI/S ratio conferred an improved survival (HR 0.48, p=0.002) but a high Foxp3+ TI/S ratio was
associated with worse survival (HR 3.91, p<0.001).
Microlocalisation of infiltrating T-lymphocytes is a powerful predictor of outcome in resected NSCLC.
@ERSpublications
Lymphocyte microlocalisation strongly influences survival in lung cancer patients undergoing
curative-intent surgery http://ow.ly/QUwbD
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Introduction
The link between inflammation and malignancy is well established [1]. From the earliest stages of cancer
development, a systemic and locoregional inflammatory response is elicited. However, it is now firmly
established that the developing tumour is capable of adapting this host immune response to create a
microenvironment conducive to its survival and progression [2].
Previous investigators have reported shown that accumulation of regulatory T-lymphocytes (Tregs) in
epithelial cancers confers a worse outcome in different tumour types [3–5]. Tregs represent a distinct
T-lymphocyte population characterised by expression of the forkhead box P3 (Foxp3) marker, a
transcriptional repressor required for maturation and immunosuppressive functionality [6]. Accumulated
evidence suggests that specific intratumoural Treg recruitment facilitates evasion by cancer cells from
immune-mediated destruction through various mechanisms, including suppression of effector T-lymphocyte
proliferation and elaboration of a network of immunosuppressive cytokines [7]. In contrast, increased
intraepithelial CD8+ tumour-infiltrating lymphocyte counts are associated with improved survival in several
cancers, suggesting that these cells act as cytotoxic antitumour cells [8, 9]. Furthermore, determination of the
ratio of CD8+ T-lymphocytes/Tregs within tumour samples has been found to be of additional prognostic
relevance in numerous cancer types [9–12].
Previous attempts to define the clinical significance of the lymphoreticular infiltrate in nonsmall cell lung
cancer (NSCLC) have yielded conflicting results, with evidence supporting beneficial [13], neutral [14] and
negative effects [15]. However, precise microlocalisation of inflammatory cells, rather than assessment of
absolute cell counts per se, appears to be critical when analysing the relationship with prognosis [16–18].
In this article, we demonstrate the prognostic relevance of different populations of infiltrating lymphocytes
in surgically-resected NSCLC, focusing in particular on the precise in situ cellular microlocalisation and
the interrelationship between pro- and anti-tumour lymphoid subsets.
Methods
Study population
The case records of all patients treated with curative-intent surgical resection for NSCLC at St James’s
Hospital (DublinQ2
¶
, Ireland) between January 2001 and January 2005 were retrospectively reviewed. We
identified 197 patients who underwent complete tumour resection and systematic lymph node dissection
with pathologically-confirmed ( p)-stages I to IIIA NSCLC according to the International System of
Staging for Lung Cancer for study [19]. Information on baseline demographics, clinicopathological
characteristics and surgical approach was collected after review of clinical notes and histopathology
reports. Outcome data, including peri-operative mortality and long-term survival, were prospectively
updated. No patient received adjuvant cytotoxic chemotherapy. The local hospital ethics committee
approved the study.
Immunohistochemistry
Archived tumour specimens from 196 patients were available for histopathological assessment. Serial
5-μm-thick sections were cut from formalin-fixed, paraffin-embedded tissue blocks and dried overnight.
One slide from each series was stained with haematoxylin–eosin for light microscopic examination to
confirm that the section contained advancing tumour edge.
We used the BondMax automated staining robot platform (Vision BioSystems, Newcastle, UK) to perform
immunohistochemical staining according to the manufacturer’s instructions. After dewaxing and 20 min
pretreatment with BondMax Antigen Epitope Retrieval Solution, diluted primary antibodies were applied.
Sections were incubated with anti-human CD3 (1:30; NovocastraQ3
¶
, Milton Keynes, UK), anti-human CD8 (1:30;
Novocastra) and anti-human Foxp3 (1:100; eBiosciencesQ4
¶
) antibody to enable detection of total, cytotoxic and
regulatory T-lymphocyte populations, respectively. Detection and visualisation of stained cells was performed
using the Bond Polymer Refine Kit (Vision BioSystems, Newcastle, UK), using 3,3’-diaminobenzidine as the
chromagen. Tissues were counterstained with Harris’s haematoxylin. Appropriate positive (human appendix)
and negative (omission of primary antibodies) controls were used in all assays.
Image acquisition and inflammatory cell quantification
The Aperio ScanScope CS slide scanner (Aperio Technologies, Vista, CA, USA) system was used to
acquire whole-slide high-resolution digitised images of tissue sections with a 20× objective. Digital images
were managed using Spectrum software (Aperio Technologies). The immunohistochemical nuclear
quantification algorithm software was adapted to develop an automated image analysis programme to
detect and quantify lymphocytes (cytoplasmic immunohistochemical staining for CD3+ and CD8+ cells
and nuclear staining for Foxp3+ cells) in regions of tumour and stroma as previously described [20] (see
the online supplementary material for additional details).
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In order to compare lymphocyte counts within the different tumour compartments, all regions of tumour
islets and stroma from five randomly selected high-powered fields were individually annotated to create
two distinct corresponding “layers” (see the online supplementary material for details). The absolute
number of immunohistochemically stained lymphocytes was determined using the novel cell detection
algorithm and reported as numbers of cells·mm-2 of tumour and stroma regions. The ratio of
corresponding tumour islet and stroma (TI/S) counts for each marker was then calculated for all patients.
Patients were classified as CD3+HIGH or CD3+LOW depending on whether the CD3+ TI/S ratio was above
or below the median value. Similarly, CD8+HIGH, CD8+LOW, Foxp3+HIGH and Foxp3+LOW groups were
established. Analysis of lymphocyte infiltration was performed without knowledge of the clinical outcome.
EGFR and KRAS mutation analysis
Gene mutations/deletions of the epidermal growth factor receptor (EGFR) tyrosine kinase domain and of
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) from the study population were also
screened for using direct Sanger sequencing in order to test whether such mutations were associated with
the different lymphocyte infiltration patterns. A full description of the methodology used is included in
the online supplementary material.
Statistical analysis
The median value was selected as a cut-point to define subgroups with respect to immunohistochemical
markers. The correlation of infiltration patterns of each lymphocyte subtype with survival was assessed
using the log-rank statistic. Statistical analysis was performed using SPSS 15.0 software (SPSS, Chicago, IL,
USA). Spearman’s ρ correlation, R-squared change and linear regression were used to test the relationship
between automated and manual analysis. Cox regression analysis, Kaplan–Meier analysis and the log-rank
test were used to illustrate the significance of various clinical characteristics. Chi-squared analysis was used
to examine for significant associations between clinicopathological characteristics and different lymphocyte
infiltration patterns. Assumption of proportional hazard was tested for all covariates. All p-values were
two-sided, with values <0.05 considered significant.
Results
Study population
The clinicopathological characteristics of the study population are presented in table 1. The mean±SD age
of the patients at time of surgery was 65.5±8.8 years (range 41–86 years). 10 patients who died within
30 days following surgery were excluded from the analysis. Overall 5-year survival for the entire cohort
was 41.3%. In a univariate analysis model, tumour size, involvement of tumour resection margins, lymph
node stage and overall stage were associated with overall survival (table 1). 11 patients with an EGFR
mutation and 11 patients with a KRAS mutation survived >30 days following surgery. Neither EGFR nor
KRAS mutation status influenced patient outcomes.
Validation of automated image analysis algorithm
Staining for each of the immunohistochemical markers was distinct and readily distinguishable from
surrounding tumour and stroma. Lymphocyte infilltration patterns showed substantial variation between
patients (fig. 1). A highly significant correlation between lymphocyte counts recorded using the manual
and the automated methods was confirmed (Spearman’s ρ=0.849, p<0.001), confirming the validity of the
automated system.
Prognostic relevance of lymphocyte infiltration
The distribution of CD3+, CD8+ and Foxp3+ lymphocytes was positively skewed and did not show a
normal distribution (data not shown). Using univariate analysis, a positive association between overall
survival and increased CD8+ TI/S ratio was observed (HR 0.44, 95% CI 0.29–0.67; p<0.001 for death;
fig. 2). The 5-year survival rate for patients with CD8+ TI/S ratios above and below the median count were
59% and 34%, respectively. As more than half the patients with a CD8+HIGH pattern were alive after
5 years, the median survival for this group could not be calculated. The median survival for patients with
CD8+LOW pattern was 30.8 months. By contrast, a striking inverse relationship between Foxp3+ Treg TI/S
ratio and overall survival was demonstrated (HR 4.86, 95% CI 3.11–7.59; p<0.001; fig. 2). The 5-year
survival rate for patients with Foxp3+ TI/S ratios above and below the median count were 20% and 69%,
respectively. The median survival for patients with a Foxp3+LOW pattern could not be determined, whereas
the median survival for those with a Foxp3+HIGH pattern was 21.2 months. A trend toward improved
survival with high CD3+ TI/S ratio was observed, although this did not reach statistical significance (HR
0.68, 95% CI 0.99–2.23; p=0.058; fig. 2).
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Next, we examined the relationship between lymphocyte counts within the individual tumour compartments
and patient outcome. A significant survival advantage was observed for patients with infiltration counts
TABLE 1 Univariate analysis of clinicopathological variables, T-lymphocyte markers and
survival
Subjects Hazard ratio (95% CI) p-value
Age years
<65 93 1
⩾65 93 1.365 (0.927–2.008) 0.115
Sex
Male 115 1
Female 71 0.378
Smoking status
Current and ex-smokers 175 1
Never-smokers 11 1.46 (0.677–3.151) 0.334
Type of surgery 0.865
Lobectomy 137 1
Bilobectomy 17 0.723 (0.442–1.761) 0.883
Pneumonectomy 32 0.654 (0.525–1.499) 0.887
Tumour size
<5 cm 124 1
⩾5 cm 62 2.155 (1.456–3.189) <0.001
Tumour stage
T1 40 1
T2 and T3 146 1.671 (0.993–2.810) 0.053
Node stage
N0 114 1
N1 and N2 72 1.527 (1.037–2.249) 0.032
WHO overall pathological stage 0.002
IA and IB 103 1
IIA and IIB 44 1.358 (0.837–2.203) 0.215
IIIA 39 2.296 (1.458–3.614) 0.000
Tumour Q6
¶
grade 0.699
1 13 1
2 110 0.745 (0.369–1.504) 0.411
3 62 0.808 (0.389–1.679) 0.567
Histological subtype 0.868
Squamous 85 1
Adenocarcinoma 84 1.036 (0.691–1.552) 0.865
Large cell 5 1.111 (0.346–3.574) 0.859
Mixed 12 1.408 (0.635–3.122) 0.400
Surgical resection margins
Negative 163 1
Positive 23 2.259 (1.355–3.766) 0.002
EGFR mutation
Negative 175 1
Positive 11 0.71 (0.255–1.976) 0.5
KRAS mutation
Negative 175 1
Positive 11 1.36 (0.582–3.171) 0.47
TI/S CD3+
<Median 86 1
⩾Median 88 0.703 (0.470–1.05) 0.086
TI/S CD8+
<Median 88 1
⩾Median 91 0.440 (0.292–0.665) <0.001
TI/S Foxp3+
<Median 90 1
⩾Median 86 4.860 (3.112–7.588) <0.001
Data are presented as n, unless otherwise stated. WHO: World Health Organization; EGFR: epidermal
growth factor receptor; KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue; TI/S: tumour
islet/stroma ratio; Foxp3: forkhead box P3.
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above the median value for CD8+ T-lymphocytes located within tumour islets (HR 0.48, 95% CI 0.33-0.72;
p<0.001) and for Foxp3+ Tregs within the peritumoral stroma (HR 0.23, 95% CI 0.15–0.36; p<0.001). In
contrast, a significantly worse outcome was associated with high stroma counts for CD3+ T-lymphocytes
(HR 1.55, 95% CI 1.03–2.3; p=0.034) and CD8+ T-lymphocytes (HR 2.19, 95% CI 1.48–3.27; p<0.001) and
for high tumour islet counts for Foxp3+ T-lymphocytes (HR 3.14, 95% CI 2.06–4.78; p<0.001). No
significant relationship between tumour islet CD3+ T-lymphocyte infiltration and prognosis was identified.
The prognostic significance of different combined CD8+/Foxp3+ TI/S infiltration was assessed by analysing
the survival patterns for patients based on the four possible combinations of CD8+ and Foxp3+ T-lymphocyte
infiltration ratios (fig. 3). Survival differences according to pattern of conjoint infiltration pattern across the
four groups were highly statistically significant (p<0.001). Patients characterised by a CD8+HIGH/Foxp3+LOW
pattern had the longest survival (77% 5-year survival rate), whereas those with a CD8+LOW/Foxp3+HIGH
pattern had particularly poor outcomes (8% 5-year survival rate). As more than half of the two groups
characterised by a Foxp3+LOW pattern were alive at 5 years (i.e. the CD8+HIGH/Foxp3+LOW and CD8+LOW/
Foxp3+LOW groups), the median survival could not be calculated. The median overall survival rates for the
CD8+HIGH/Foxp3+HIGH and CD8+LOW/Foxp3+HIGH groups were 31.0 months and 17.2 months, respectively.
The proportional hazards assumption was employed to assess whether the TI/S ratios for the different
lymphocyte subsets were independent predictors of survival (table 2). Clinicopathological variables included
as covariates were tumour size, tumour stage, lymph node stage, overall p-stage, surgical margins and CD3+,
CD8+ and Foxp3+ T-lymphocyte TI/S infiltration ratios. These parameters were chosen because of their
relative prognostic significance by univariate analysis (p<0.1). A high CD8+ TI/S ratio was independently
associated with improved survival (HR 0.48, 95% CI 0.30–0.76; p=0.002), whereas a high Foxp3+ TI/S ratio
emerged as an independent predictor of worse survival (HR 3.91, 95% CI 2.33–6.55; p<0.001). Interestingly,
both CD8+ and Foxp3+ TI/S ratios were stronger prognostic variables than p-stage by multivariate analysis.
Patients with EGFR and KRAS mutations were distributed approximately evenly across the different
lymphocyte infiltration pattern groups, indicating a lack of correlation between mutation status and any of
the lymphocyte infiltration patterns, either alone or by combination lymphocyte ratios (online
supplementary material).
FIGURE 1 Immunohistochemistry
lymphocyte Q5
¶
infiltration patterns.
Photomicrographs demonstrating
predominant tumour islet
infiltration by a) CD3+, c) CD8+ and
e) forkhead box P3 (Foxp3)+
T-lymphocytes and predominant
stroma infiltration by b) CD3+, d)
CD8+ and f) Foxp3+ T-lymphocytes.
a) b)
c) d)
e) f)
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As an internal validation for the methodology employed to determine the prognostic value associated with
assessment of T-lymphocyte TI/S ratio, the study population was split into test and validation cohorts. The
median TI/S values derived from the first 100 patients (test cohort) for the CD8+ and Foxp3+ markers
were established. These new cut-point values were then applied to dichotomise the remainder of the study
population (validation cohort) to examine the reproducibility of the method (fig. 4). Using this approach,
the Foxp3+ TI/S ratio remained a statistically significant prognostic variable in both the test (HR 3.5, 95%
CI 2.01–6.13; p<0.001) and validation cohorts (HR 8.05, 95% CI 3.33–19.47; p<0.001). The CD8+
T-lymphocyte TI/S ratio showed a trend toward statistical significance in the test cohort (HR 1.60, 95% CI
0.95–2.70; p=0.076) and was significant in the validation cohort (HR 5.70, 95% CI 2.01–16.15; p=0.001).
1.0 CD8+HIGH/Foxp3+LOW (n=53)
CD8+LOW/Foxp3+LOW (n=34)
CD8+HIGH/Foxp3+HIGH (n=33)
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0.8
0.6
0.4
Cu
m
ul
at
iv
e 
su
rv
iv
al
0.2
0.0
0 20 40
Survival months
60 80
p<0.001
100
FIGURE 3 Kaplan–Meier survival
curves according to combined
CD8+/forkhead box P3 (Foxp3)+
T-lymphocyte tumour islet/stroma
(TI/S) ratio infiltration pattern.
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FIGURE 2 Kaplan–Meier survival curves according to tumour islet/stroma (TI/S) ratio infiltration patterns for
a) CD8+, b) forkhead box P3 (Foxp3)+ and c) CD3+ T-lymphocytes.
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TABLE 2 Multivariate analysis results of lymphocyte infiltration tumour islet/stroma (TI/S) ratio
and clinicopathological variables#
Hazard ratio (95% CI) p-value
TI/S CD3+
<Median 1
>Median 0.65 (0.41–1.02) 0.064
TI/S CD8+
<Median 1
>Median 0.481 (0.30–0.764) 0.002
TI/S Foxp3+
<Median 1
>Median 3.91 (2.33–6.55) <0.001
Tumour size
<5 cm 1
⩾5 cm 2.19 (1.39–3.44) 0.001
Overall p-stage
IA and IB 1
IIA and IIB 1.8 (1.06–3.09) 0.030
IIIA 1.9 (1.13–3.31) 0.015
Overall 0.024
FoxP3: forkhead box P3; p: pathologically confirmed. #: the following were included as co-variates: tumour
size, tumour stage, lymph node stage, World Health Organization overall stage, presence/absence of
tumour involvement in resection margins and TI/S ratios for CD3+, CD8+ and Foxp3+ T-lymphocytes.
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FIGURE 4 Kaplan–Meier survival curves for test and validation cohorts for CD8+ and forkhead box P3 (Foxp3)+
T-lymphocyte tumour islet/stroma (TI/S) ratios. a) CD8+ test cohort; b) FoxP3+ test cohort; c) CD8+ validation
cohort; FoxP3+ validation cohort.
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Correlation of immune infiltration with clinicopathological variables
Chi-squared analysis was used to examine for significant associations between clinicopathological
characteristics and different lymphocyte infiltration patterns. For this analysis, the cell-count data were
dichotomised about the median value. A significant correlation between CD8+ and Foxp3+ TI/S infiltration
patterns was confirmed (Chi-squared 3.97, p=0.04). There was no association between lymphocyte markers
and any of the examined clinicopathological variables. There was no correlation between pathological stage
and CD8+ ratio or Foxp3+ TI/S infiltration patterns. A weakly statistically significant correlation between
overall stage and the combination CD8+/Foxp3+ infiltration ratio was shown; however, this association was
only demonstrable when stages IA and IB, and IIA and IIB were combined.
Discussion
In this study, we performed a detailed evaluation of the tumour microenvironment in NSCLC surgical
specimens. Focusing on cellular microlocalisation in particular, our results showed that regional distribution
of T-lymphocyte subsets is a strong predictor of outcome in a large population of surgically-resected
NSCLC patients, independent of tumour stage and other clinicopathological variables. Patients with a
higher proportion of Foxp3+ T-lymphocytes within tumour islets as opposed to in surrounding peritumoral
stroma had a significantly worse outcome. The opposite pattern was observed for CD8+ T-lymphocytes,
such that a relatively higher intratumoral infiltration by this immune population conferred a favourable
prognosis, whereas an increased stromal CD8+ count was associated with a poor prognosis.
Both positive and negative effects on tumour invasion, growth, metastasis and clinical outcome have been
attached to the presence of lymphocytes within solid tumours. The finding that high levels of tumour islet
Foxp3+ Tregs predict a strikingly worse outcome in NSCLC is consistent with observations from other
investigators. In their landmark paper, WOO et al. [21] demonstrated an increased percentage of CD4+CD25+
Tregs in NSCLC and ovarian cancer. Using a semi-quantitative scoring system, PETERSEN et al. [22]
subsequently showed that stage I NSCLC patients with increased intratumoral Treg accumulation relative to
total infiltrating lymphocyte counts were at increased risk of disease relapse. SHIMIZU et al. [23] also showed
that intratumoral Treg infiltration predicted shortened relapse-free survival following surgical resection for
NSCLC, probably due to elaboration by these cells of the immunosuppressive enzyme cyclooxygenase-2. A
key feature of Tregs is their ability to inhibit other immune populations (including CD8+ T-lymphocytes) by
direct cellular contact, and active recruitment of Tregs to the tumour microenvironment may thereby
facilitate the evasion of cancer cells of immune detection and destruction [7].
Different investigators have demonstrated that intratumoral infiltration by T-lymphocytes expressing the
CD8+ marker confers a survival advantage in colorectal [24], ovarian [25] and cervical [26] cancers, among
others. Effective antitumour activity has been proposed as the biological explanation for these findings and
this phenomenon may also explain the significant survival gain in patients in our series with a high
intratumoral CD8+ T-lymphocyte counts. Indeed, our results show some similarities to those of other
investigators evaluating immunomechanisms of infiltrating lymphocytes in NSCLC. KAWAI et al. [13]
examined biopsy specimens from patients with stage IV disease and found that a predominant CD8+
T-lymphocyte infiltration within tumour islets was associated with improved survival. By contrast, AL-SHIBLI
et al. [27] found that high numbers of stromal CD8+ T-lymphocytes was an independent favourable
prognostic marker and that an increase in epithelial CD8+ lymphocytes correlated with poor survival, though
only in univariate analysis. However, the scoring system used to quantify tumour and stroma lymphocyte
counts was based on approximate percentages of lymphocytes as a proportion of total nucleated cells per
compartment. By contrast, in the current study, absolute numbers of lymphocytes were automatically counted
in each region and expressed per unit area to yield an exact value for each patient. This is of particluar
importance, since assessment of the precise microlocalisation of different immune populations rather than
determination of absolute cell counts per se appears to be critical when characterising leukocyte phenotype to
investigate the relationship between inflammatory cell infiltration patterns and prognosis [16, 18].
Our data also suggest that an interrelationship between effector and suppressor cell ratios and prognosis
exists. The 5-year survival rate for patients with a combined low TI/S CD8+ ratio and high TI/S Foxp3+
ratio after curative-intent surgery was only 8%, compared to 77% for patients with the opposite pattern.
Interestingly, patients with low TI/S ratios for both Foxp3+ and CD8+ T-lymphocytes fared better than
those with corresponding high ratios. These results suggest that while microlocalisation of CD8+
T-lymphocyte populations is an important determinant of postoperative survival, it is the presence or
absence of Tregs that exerts greatest influence on outcome. Thus, while the absolute numbers of different
lymphocyte populations infiltrating NSCLC is important, the balance of tumour-promoting (Tregs) and
tumour-limiting (CD8+ cytotoxic cells) mechanisms may be of even greater relevance. The emergence of
the Foxp3+ TI/S ratio as an independent predictor of outcome in our population using a multivariable
analysis model and the finding that this parameter remained prognostically relevent after internal
8 DOI: 10.1183/13993003.00176-2014
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validation further supports this hypothesis. Furthermore, our results with respect to the variations in
patient outcome according to the CD8+/Foxp3+ T-lymphocyte infiltration ratio in NSCLC are consistent
with those of investigators studying other tumour types showing that the intratumoral balance of
regulatory and cytotoxic T-lymphocyte subsets is an independent predictor of outcome. A clear association
between low CD8+/Treg intratumoral infiltration ratio and adverse prognosis has been previously reported
in cervical [10] and gastric [11] cancer, whereas a high infiltration ratio confers better survival in ovarian
cancer [9] and colorectal [12] cancers.
There are several possible biological explanations that may account for the apparent opposing effects of
CD8+ and Foxp3+ T-lymphocytes in NSCLC. A simple hypothesis is that CD8+ cells within tumour islets
are functionally activated and control tumour growth through elaboration of cytokines that target and kill
cancer cells, whereas Tregs exhibit an immunosuppressive phenotype that facilitates cancer cell survival
and proliferation. Thus, a relative increase in the intratumoral accumulation of Tregs over effector
populations might be sufficient to overcome cytotoxic T-lymphocyte function [28]. A variety of
mechanisms are believed to promote this suppressive functionality, including cell–cell contact, local
competition for growth factors and secretion of inhibitory cytokines [29]. Indeed, there is compelling
evidence that Tregs inhibit effective CD8+ T-lymphocyte cytotoxic activity via the transforming growth
factor-β signalling pathway [30]. In this manner, an excess of Tregs within tumour islets may blunt host
effector mechanisms, enabling cancer progression. Similarly, immunotherapeutic strategies that deplete
Treg populations without concomitant modulation of cytotoxic T-cell activity are insufficiently capable of
restoring effective anti-tumour immunity [31]. Conversely, an increased cytotoxic T-lymphocyte
infiltration in conjunction with complete abolishment of Tregs is characteristic in patients with a complete
pathological response to neoadjuvant chemotherapy [32]. In this regard, it is important to emphasise that
no patient in our cohort received postoperative chemotherapy. This is of particular relevance and we
believe a strength of our study, since adjuvant cancer treatments can radically alter immune function and
could potentially act as a confounder with respect to outcome.
The variable prognosis shown in our study population associated with differential tumour lymphocyte
infiltration patterns supports the hypothesis that different phenotypes of tumour immunogenicity may exist in
lung cancer. Indeed, recent data suggest that tumour immune evasion is modulated via two distinct host
inflammatory cell and cytokine patterns. Tumours that show abundant adaptive and innate inflammatory cell
infiltration characterise the first type. This subset is capable of resisting host anticancer efforts through a
dominant inhibitory effect on the immune system–suppressive pathways and by upregulation of a
tumour-promoting cytokine profile, mediated by Tregs in conjuction with other inflammatory cell populations,
such as M2 alternatively activated macrophages and dendritic cells (DCs) [7, 18, 33], among others. Although
CD8+ effector T-lymphocytes form part of the intratumoral cellular influx, these become functionally inhibited
by the immunosuppressive cytokine milieu. The second major phenotype shows a pauci-immune pattern, with
low levels of both immune cell infiltration and chemokine expression. Such tumours appear to be capable of
resisting host defence mechanisms through immune system exclusion and/or “ignorance”.
It is now recognised that adaptive immune antitumour cellular elements may originate from regions other
than classic primary and secondary lymphoid organs. In this regard, the presence of stromal tertiary
lymphoid structures (TLS), comprising aggregates of mature dendritic cells and T-lymphocytes surrounded
by follicular B-lymphocytes, also exert prognostic influence in different cancers. In early-stage NSCLC it
has previously been reported that the density of mature dendritic cells in TLS is a strong predictor of
mortality [34]. Moreover, similar to our observation that low CD8+ T-lymphocyte infiltration into
tumours predicts an unfavourable outcome, a group of French investigators have observed that both low
levels of TLS derived B-lymphocytes and dendritic cells and combined low densities of mature dencritic
cells and CD8+ T-lymphocytes identifies NSCLC patient subgroups at significantly increased risk of death
[35, 36]. These findings emphasise that tumour-antigen specific humoral responses are also a critical
component of host anticancer defences. However, a complete understanding of the complex interactions
between CD8+ and Foxp3+ T-lymphocytes, B-lymphocytes and dendritic cells in the NSCLC contexture is
lacking and merits further investigation.
The accumulated evidence, supported by our observations, of distinct immunological phenotypes based on
the relative presence or absence of T-cell based inflammatory patterns also has potentially critical
implications for clinical translation. For example, tumours incapable of supporting trafficking of activated
cytotoxic T-lymphocytes into the tumour microenvironment may inherently be resistant to
immunotherapeutic intervention and confer less favourable clinical responses.
Our findings may be of relevance to the developing field of NSCLC immunotherapy, in particular those
agents that act on the immune checkpoint pathway inhibitory molecules cytotoxic T-lymphocyte
associated antigen (CTLA)-4 and programmed cell death protein (PD)-1, as well as the binding partner of
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the latter, PD-L1. Approval has recently been granted for the monoclonal antibody PD-1 inhibitor
nivolumab for metastatic squamous NSCLC that has failed chemotherapy, and since Tregs highly express
PD-1 [37], it would be of interest to specifically examine the relative impact of nivolumab (and other
PD-1/PD-L1 inhibitors) on patients exhibiting high versus low intratumoral Foxp3+ lymphocyte
infiltration. Moreover, recent data have highlighted that anti-CTLA4 antibodies deplete intratumoral Treg
populations [38] and one might speculate that those patients with the poorest prognosis in our study,
based on lymphocyte infiltration characteristics, might potentially see the greatest benefit from approaches
that inhibit CTLA-4, either alone or in combination with anti-PD-1/PD-L1 antibodies. Testing this
hypothesis may also help establish whether it is possible to better select patients for enrolment into future
clinical studies of approved and/or investigational agents that target the immune checkpoint pathway.
There is recent debate regarding the plasticity of Foxp3 expression and its relationship to Treg function
[39]. Indeed, some cells we identified may have had only transient Foxp3 expression. However, this
possibility does not alter the significance of our findings. A thorough evaluation of the cytokine profiles
within tumour and stroma regions in patients with different lymphocyte infiltration patterns may help
clarify the biological mechanisms associated with our findings, particularly given the emerging interest in
tumour-specific vaccine therapies in NSCLC [40].
In conclusion, our data suggest that assessment of T-lymphocyte microlocalisation may help identify
individuals at risk of early disease relapse despite apparent complete surgical resection. Internal test and
validation studies performed suggest that Foxp3+ and possibly CD8+ TI/S ratios could have a role in
helping determine which patients should receive adjuvant treatments. Future immunotherapeutic strategies
capable of downregulating intratumoral Treg responses while enhancing corresponding effector CD8+
T-lymphocyte activity may be worth pursuing.
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